|
1
|
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
|
N Engl J Med
|
2001
|
2.83
|
|
2
|
Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction.
|
Circulation
|
2001
|
2.09
|
|
3
|
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
|
J Am Coll Cardiol
|
1997
|
2.08
|
|
4
|
Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes.
|
J Med Genet
|
2004
|
1.94
|
|
5
|
Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
|
Circulation
|
1998
|
1.93
|
|
6
|
Influence of labetalol on cocaine-induced coronary vasoconstriction in humans.
|
Am J Med
|
1993
|
1.90
|
|
7
|
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.
|
Circulation
|
2001
|
1.83
|
|
8
|
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators.
|
Eur Heart J
|
2000
|
1.73
|
|
9
|
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
|
Circulation
|
2001
|
1.70
|
|
10
|
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial.
|
J Am Coll Cardiol
|
2000
|
1.63
|
|
11
|
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
|
Eur Heart J
|
2004
|
1.59
|
|
12
|
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.
|
Circulation
|
1999
|
1.59
|
|
13
|
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
|
N Engl J Med
|
1999
|
1.55
|
|
14
|
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
|
Circulation
|
2001
|
1.54
|
|
15
|
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.
|
Eur Heart J
|
2002
|
1.50
|
|
16
|
Unexpected mortality reduction with abciximab for in-stent restenosis.
|
J Invasive Cardiol
|
2000
|
1.38
|
|
17
|
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network.
|
J Am Coll Cardiol
|
2001
|
1.27
|
|
18
|
Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin.
|
J Am Coll Cardiol
|
1991
|
1.12
|
|
19
|
Subacute stent thrombosis: evolving issues and current concepts.
|
J Am Coll Cardiol
|
1996
|
1.09
|
|
20
|
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy.
|
Circulation
|
2001
|
1.07
|
|
21
|
Association of genetic variants in the HDL receptor, SR-B1, with abnormal lipids in women with coronary artery disease.
|
J Med Genet
|
2003
|
1.05
|
|
22
|
First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions.
|
Circulation
|
1997
|
1.03
|
|
23
|
Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
|
Circulation
|
2000
|
0.93
|
|
24
|
Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials.
|
J Thromb Haemost
|
2012
|
0.92
|
|
25
|
Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators.
|
Am J Cardiol
|
1999
|
0.90
|
|
26
|
Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor.
|
AJNR Am J Neuroradiol
|
1997
|
0.89
|
|
27
|
A critical appraisal of platelet glycoprotein IIb/IIIa inhibition.
|
J Am Coll Cardiol
|
2000
|
0.88
|
|
28
|
Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
|
Circulation
|
2000
|
0.87
|
|
29
|
Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes.
|
Am Heart J
|
1999
|
0.86
|
|
30
|
Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials.
|
Am Heart J
|
2000
|
0.85
|
|
31
|
Hemodynamic effects of intranasal cocaine in humans.
|
J Am Coll Cardiol
|
1992
|
0.83
|
|
32
|
beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise.
|
Circulation
|
2001
|
0.83
|
|
33
|
Monitoring antiplatelet therapy: What is the best method?
|
Clin Pharmacokinet
|
2000
|
0.82
|
|
34
|
The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.
|
J Am Coll Cardiol
|
1998
|
0.82
|
|
35
|
The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable.
|
Catheter Cardiovasc Interv
|
2001
|
0.81
|
|
36
|
The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade.
|
Cleve Clin J Med
|
1998
|
0.81
|
|
37
|
Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients.
|
Drugs Aging
|
2000
|
0.81
|
|
38
|
Restenosis--an open file.
|
Clin Cardiol
|
1996
|
0.80
|
|
39
|
In-stent restenosis: update on intracoronary radiotherapy.
|
Cleve Clin J Med
|
2001
|
0.80
|
|
40
|
Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET.
|
Curr Opin Cardiol
|
2001
|
0.79
|
|
41
|
Troponins in acute coronary syndromes: More TACTICS for an early invasive strategy.
|
JAMA
|
2001
|
0.79
|
|
42
|
Coronary intravascular ultrasound: diagnostic and interventional applications.
|
Coron Artery Dis
|
1995
|
0.79
|
|
43
|
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
|
J Thromb Thrombolysis
|
2001
|
0.79
|
|
44
|
Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment.
|
Heart
|
2005
|
0.79
|
|
45
|
Achieving tissue-level perfusion in the setting of acute myocardial infarction.
|
Am J Cardiol
|
2000
|
0.79
|
|
46
|
Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation.
|
J Am Coll Cardiol
|
1998
|
0.78
|
|
47
|
Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry.
|
Am Heart J
|
1999
|
0.76
|
|
48
|
Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT.
|
Am Heart J
|
2001
|
0.75
|
|
49
|
Plasma lipoprotein(a) concentrations are not elevated by cardiopulmonary bypass.
|
Atherosclerosis
|
1993
|
0.75
|
|
50
|
Bedside activated partial thromboplastin time monitoring: just a matter of time?
|
Am Heart J
|
1999
|
0.75
|
|
51
|
Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.
|
Circulation
|
1999
|
0.75
|
|
52
|
Preinfarction angina.
|
N Engl J Med
|
1996
|
0.75
|
|
53
|
TIMI flow and surrogate end points: what you see is not always what you get.
|
Am Heart J
|
1998
|
0.75
|
|
54
|
Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
|
Heart Vessels
|
1997
|
0.75
|
|
55
|
Thrombolytic therapy for acute myocardial infarction.
|
Catheter Cardiovasc Interv
|
2001
|
0.75
|
|
56
|
Invasive vs conservative management of non-Q-wave myocardial infarction.
|
Cleve Clin J Med
|
1999
|
0.75
|
|
57
|
Another step toward resolving the contrast controversy.
|
J Am Coll Cardiol
|
1996
|
0.75
|
|
58
|
The TARGET trial: hit or miss?
|
Eur Heart J
|
2002
|
0.75
|
|
59
|
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes.
|
Curr Cardiol Rep
|
1999
|
0.75
|
|
60
|
Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspective.
|
J Emerg Med
|
1999
|
0.75
|
|
61
|
Glycoprotein IIb/IIIa antagonist and fibrinolytic agents: new therapeutic regimen for acute myocardial infarction.
|
J Invasive Cardiol
|
2000
|
0.75
|
|
62
|
Peripartum myocardial infarction.
|
Am Heart J
|
1993
|
0.75
|
|
63
|
Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors.
|
J Thromb Thrombolysis
|
1999
|
0.75
|
|
64
|
Aspirin, ticlopidine, and clopidogrel in acute coronary syndromes: underused treatments could save thousands of lives.
|
Cleve Clin J Med
|
2000
|
0.75
|
|
65
|
"Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry.
|
J Thromb Thrombolysis
|
2001
|
0.75
|
|
66
|
GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
|
Cleve Clin J Med
|
2001
|
0.75
|
|
67
|
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
|
Minerva Cardioangiol
|
2002
|
0.75
|
|
68
|
Applications of anti-platelet monitoring in catheterization laboratory.
|
J Thromb Thrombolysis
|
2000
|
0.75
|
|
69
|
Platelet glycoprotein IIb/IIIa receptor antagonists.
|
Expert Opin Pharmacother
|
2000
|
0.75
|